The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease

Thrombosis and Haemostasis

Volumn 112, Issue 3, 2014, Pages 589-597

  Gurbel, Paul A ^a   Bergmeijer, Thomas O ^b   Tantry, Udaya S ^a   Ten Berg, Jurrien M ^b   Angiolillo, Dominick J ^c   James, Stefan ^d   Lindahl, Tomas L ^e   Svensson, Peter ^f   Jakubowski, Joseph A ^g   Brown, Patricia B ^g   Duvvuru, Suman ^g   Sundseth, Scott ^h   Walker, Joseph R ⁱ   Small, David ^g   Moser, Brian A ^g   Winters, Kenneth J ^g   Erlinge, David ^f  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g ELI LILLY AND COMPANY   (United States)

^h Cabernet Pharmaceuticals   (United States)

ⁱ DAIICHI SANKYO INC   (United States)

Author keywords

Clopidogrel; Coronary artery disease; CYP2C19; Platelet reactivity; Prasugrel

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; TICLOPIDINE;

AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; CYTOCHROME P450 2C19 GENE; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; THROMBOCYTE RELEASE REACTION; VASODILATOR-ASSOCIATED STIMULATED PHOSPHOPROTEIN PLATELET REACTIVITY INDEX; ANALOGS AND DERIVATIVES; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CLINICAL PROTOCOLS; CORONARY ARTERY DISEASE; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84911095533     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-10-0891     Document Type: Article

References (11)

1. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
2. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009; 30: 1744-1752.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
4. Riesmeyer JS, Salazar DE, Weerakkody GJ, et al. Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy. J Clin Pharmacol 2012; 52: 789-797.
5. Erlinge D, Gurbel PA, James S, et al. Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in nonelderly patients: The GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 2013; 62: 577-583.
6. Erlinge D, ten Berg J, Foley D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 2012; 60: 2032-2040.
7. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010; 4: 278-281.
8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
9. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312-1319.
10. Cuisset T, Loosveld M, Morange PE, et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 2012; 5: 1280-1287.
11. Grosdidier C, Quilici J, Loosveld M, et al. Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. Am J Cardiol 2013; 111: 985-990.